Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | MAOB | P27338 | 2/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 2/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.34 |
| ▸ | RELA | Q04206 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 2/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30325556 | 1.00 | BTK (0.36) | BTKGAAMAOBMAOAEPHX1 | |
| SCHEMBL22590347 | 1.00 | BTK (0.36) | BTKGAAMAOBMAOAEPHX1 | |
| SCHEMBL30325592 | 1.00 | BTK (0.36) | BTKGAAMAOBMAOAEPHX1 | |
| SCHEMBL18258124 | 1.00 | BTK (0.36) | BTKGAAMAOBMAOAEPHX1 | |
| SCHEMBL31340838 | 0.86 | BTK (0.34) | BTKGAAMAOBMAOAEPHX1 | |
| SCHEMBL25145140 | 0.85 | BTK (0.38) | BTKGAAMAOBEPHX1EPHX2 | |
| SCHEMBL1468743 | 0.85 | BTK (0.38) | BTKGAAMAOBEPHX1EPHX2 | |
| SCHEMBL1468748 | 0.85 | BTK (0.38) | BTKGAAMAOBEPHX1EPHX2 | |
| SCHEMBL18940559 | 0.85 | BTK (0.38) | BTKGAAMAOBEPHX1EPHX2 | |
| SCHEMBL13624954 | 0.85 | BTK (0.38) | BTKGAAMAOBEPHX1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10815218-B2 | Benzoimidazole derivatives as PAD4 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-10-27 | — | — | US | disclosed |
| US-10407407-B2 | Benzoimidazole derivatives as PAD4 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10407407-B2 | Benzoimidazole derivatives as PAD4 inhibitors | PADI4, PADI1, PADI2 | BTK 10/4885GAA 1439/4885MAOB 942/4885 |
| US-10815218-B2 | Benzoimidazole derivatives as PAD4 inhibitors | PADI4, PADI1, PADI2 | BTK 10/4885GAA 1439/4885MAOB 942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.